These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. Hainsworth JD; Spigel DR; Burris HA; Waterhouse D; Clark BL; Whorf R J Clin Oncol; 2010 May; 28(13):2131-6. PubMed ID: 20368560 [TBL] [Abstract][Full Text] [Related]
5. The therapy of kidney cancer with biomolecular drugs. Di Lorenzo G; Buonerba C; Biglietto M; Scognamiglio F; Chiurazzi B; Riccardi F; Cartenì G Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S16-20. PubMed ID: 21129605 [TBL] [Abstract][Full Text] [Related]
7. Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma. Guillot A; Levy A; Pacaut C; Collard O; Massard C; Merrouche Y; Magné N Clin Genitourin Cancer; 2012 Sep; 10(3):147-52. PubMed ID: 22796529 [TBL] [Abstract][Full Text] [Related]
8. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308 [TBL] [Abstract][Full Text] [Related]
9. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. Ainsworth NL; Lee JS; Eisen T Expert Rev Anticancer Ther; 2009 Dec; 9(12):1793-805. PubMed ID: 19954291 [TBL] [Abstract][Full Text] [Related]
10. Improving outcomes in patients with advanced renal cell carcinoma. Sosman JA Expert Rev Anticancer Ther; 2008 Mar; 8(3):481-90. PubMed ID: 18366295 [TBL] [Abstract][Full Text] [Related]
12. How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma. Escudier B J Clin Oncol; 2010 May; 28(13):2125-6. PubMed ID: 20368540 [No Abstract] [Full Text] [Related]
13. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma. Figlin RA; Pierce WC; Belldegrun A Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686 [No Abstract] [Full Text] [Related]
14. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. Parton M; Gore M; Eisen T J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544 [TBL] [Abstract][Full Text] [Related]
15. Combination systemic therapy for advanced renal cell carcinoma. Miller RE; Larkin JM Oncologist; 2009 Dec; 14(12):1218-24. PubMed ID: 19939892 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapeutic strategies in kidney cancer--when TKIs are not enough. Biswas S; Eisen T Nat Rev Clin Oncol; 2009 Aug; 6(8):478-87. PubMed ID: 19546865 [TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667 [TBL] [Abstract][Full Text] [Related]
19. Interferon alpha for the treatment of advanced renal cancer. Ravaud A; Dilhuydy MS Expert Opin Biol Ther; 2005 Jun; 5(6):749-62. PubMed ID: 15952906 [TBL] [Abstract][Full Text] [Related]
20. A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma. Figlin RA Immunotherapy; 2014; 6(3):261-8. PubMed ID: 24354908 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]